Polyhydroxylated Fullerene C₆₀(OH)₄₀ Nanofilms Promote the Mesenchymal–Epithelial Transition of Human Liver Cancer Cells via the TGF-β1/Smad Pathway

References

• Tang Z, He J, Zou J, Yu S, Sun X, Qin L. Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC. PeerJ. 2021;9:e11200. doi:10.7717/peerj.11200
   PubMed Web of Science ®Google Scholar
• Kuznietsova H, Dziubenko N, Herheliuk T, et al. Water-soluble pristine C60 fullerene inhibits liver alterations associated with hepatocellular carcinoma in rat. Pharmaceutics. 2020;12(9):794. doi:10.3390/pharmaceutics12090794
   PubMed Web of Science ®Google Scholar
• Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115–4127. doi:10.3748/wjg.v20.i15.4115
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Moustakas A. Epithelial-mesenchymal transition and metastasis under the control of transforming growth factor. Int J Mol Sci. 2018;19(19):3672. doi:10.3390/ijms19113672
   PubMedGoogle Scholar
• Choi SS, Diehl AM. Epithelial‐to‐mesenchymal transitions in the liver. Hepatology. 2009;50:2007–2013. doi:10.1002/hep.23196
   PubMed Web of Science ®Google Scholar
• Wendt M, Allington TM, Schiemann WP. Mechanisms of epithelial-mesenchymal transition by TGF-β. Future Oncol. 2009;5(8):1145–1168. doi:10.2217/fon.09.90
   PubMedGoogle Scholar
• Cordani M, Strippoli R, Somoza Á. Nanomaterials as inhibitors of epithelial mesenchymal transition in cancer treatment. Cancers. 2019;12(1):25. doi:10.3390/cancers12010025
   PubMedGoogle Scholar
• Parekh A, Weaver AM. Regulation of cancer invasiveness by the physical extracellular matrix environment. Cell Adhes Migr. 2009;3(3):288–292. doi:10.4161/cam.3.3.8888
   PubMed Web of Science ®Google Scholar
• Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010;70(8):3005–3008. doi:10.1158/0008-5472.CAN-09-4041
   PubMedGoogle Scholar
• Harikrishnan LS, Warrier J, Tebben AJ, et al. Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI). Bioorgan Med Chem. 2018;26(5):1026–1034. doi:10.1016/j.bmc.2018.01.014
   PubMedGoogle Scholar
• Verrecchia F, Mauviel A. Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118(2):211–215. doi:10.1046/j.1523-1747.2002.01641.x
   PubMed Web of Science ®Google Scholar
• Luo Y, Ren Z, Du B, et al. Structure identification of ViceninII extracted from Dendrobium officinale and the reversal of TGF-β1-induced epithelial–mesenchymal transition in lung adenocarcinoma cells through TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. Molecules. 2019;24:144. doi:10.3390/molecules24010144
   PubMedGoogle Scholar
• Kume K, Haraguchi M, Hijioka H, et al. The transcription factor Snail enhanced the degradation of E-cadherin and desmoglein 2 in oral squamous cell carcinoma cells. Biochem Bioph Res Co. 2013;430(3):889–894. doi:10.1016/j.bbrc.2012.12.060
   PubMedGoogle Scholar
• Abarrategi A, Gutiérrez MC, Moreno-Vicente C, et al. Multi-wall carbon nanotube scaffolds for tissue engineering purposes. Biomaterials. 2008;29:94–102. doi:10.1016/j.biomaterials.2007.09.021
   PubMed Web of Science ®Google Scholar
• Essid N, Chambard JC, Elgaaïed AB. Induction of epithelial-mesenchymal transition (EMT) and Gli1 expression in head and neck squamous cell carcinoma (HNSCC) spheroid cultures. Bosnian J Basic Med. 2018;18(4):336. doi:10.17305/bjbms.2018.3243
   PubMed Web of Science ®Google Scholar
• Joseph JP, Harishankar MK, Pillai AA, Devi A. Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 2018;80:23–32. doi:10.1016/j.oraloncology.2018.03.004
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen C, Qian P, et al. Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun. 2015;23:5988. doi:10.1038/ncomms6988
   Google Scholar
• Sharoyko VV, Iamalova NR, Ageev SV, et al. In vitro and in silico investigation of water-soluble fullerenol C60(OH)24: bioactivity and biocompatibility. J Phys Chem B. 2021;125(32):9197–9212. doi:10.1021/acs.jpcb.1c03332
   PubMedGoogle Scholar
• Bolshakova O, Borisenkova A, Suyasova M, et al. In vitro and in vivo study of the toxicity of fullerenols С60, С70 and С120О obtained by an original two step method. Mater Sci Eng C. 2019;104:109945. doi:10.1016/j.msec.2019.109945
   PubMed Web of Science ®Google Scholar
• Kovel ES, Kicheeva AG, Vnukova NG, Churilov GN, Stepin EA, Kudryasheva NS. Toxicity and antioxidant activity of fullerenol c60, 70 with low number of oxygen substituents. Int J Mol Sci. 2021;22(12):6382. doi:10.3390/ijms22126382
   PubMedGoogle Scholar
• Shimizu K, Kubot R, Kobayashi N, et al. Cytotoxic effects of hydroxylated fullerenes in three types of liver cells. Materials. 2013;6(7):2713–2722. doi:10.3390/ma6072713
   PubMedGoogle Scholar
• Jiao F, Liu Y, Qu Y, et al. Studies on anti-tumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon. 2010;48(8):2231–2243. doi:10.1016/j.carbon.2010.02.032
   Google Scholar
• Prylutska SV, Grebinyk AG, Lynchak OV, Byelinska IV, Cherepanov VV. In vitro and in vivo toxicity of pristine C60 fullerene aqueous colloid solution. Fuller Nanotub Carbon Nanostructures. 2019;27(9):715–728. doi:10.1080/1536383X.2019.1634055
   Web of Science ®Google Scholar
• Chen C, Xing G, Wang J, et al. Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 2005;5(10):2050–2057. doi:10.1021/nl051624b
   PubMed Web of Science ®Google Scholar
• Zhu X, Cirovic S, Shaheen A, Xu W. Investigation of fullerenol-induced changes in poroelasticity of human hepatocellular carcinoma by AFM-based creep tests. Biomech Model Mechan. 2018;17(3):665–674. doi:10.1007/s10237-017-0984-5
   PubMedGoogle Scholar
• Sosnowska M, Kutwin M, Jaworski S, et al. Mechano-signalling, induced by fullerene C60 nanofilms, arrests the cell cycle in the G2/M phase and decreases proliferation of liver cancer cells. Int J Nanomed. 2019;14:6197. doi:10.2147/IJN.S206934
   PubMed Web of Science ®Google Scholar
• Sosnowska M, Kutwin M, Strojny B, et al. Graphene oxide nanofilm and chicken embryo extract decrease the invasiveness of HepG2 liver cancer cells. Cancer Nanotechnol. 2021;12(1):1–33. doi:10.1186/s12645-020-00073-5
   PubMed Web of Science ®Google Scholar
• Sosnowska M, Kutwin M, Strojny B, et al. Diamond nanofilm normalizes proliferation and metabolism in liver cancer cells. Nanotechnol Sci Appl. 2021;14:115. doi:10.2147/NSA.S322766
   PubMed Web of Science ®Google Scholar
• Roy P, Bag S, Chakraborty D, Dasgupta S. Exploring the inhibitory and antioxidant effects of fullerene and fullerenol on ribonuclease A. ACS Omega. 2018;3(9):12270–12283. doi:10.1021/acsomega.8b01584
   PubMedGoogle Scholar
• Dmitrenko ME, Penkova AV, Kuzminova AI, et al. Development and investigation of novel polyphenylene isophthalamide pervaporation membranes modified with various fullerene derivatives. Sep Purif Technol. 2019;226:241–251. doi:10.1016/j.seppur.2019.05.092
   Google Scholar
• Takaya Y, Tachika H, Hayashi T, Kokubo K, Suzuki K. Performance of water-soluble fullerenol as novel functional molecular abrasive grain for polishing nanosurfaces. CIRP Ann. 2009;58(1):495–498. doi:10.1016/j.cirp.2009.03.118
   Google Scholar
• Liu L, Li N, Zhang Q, Zhou J, Lin L, He X. Inhibition of ERK1/2 signaling impairs the promoting effects of TGF-β1 on hepatocellular carcinoma cell invasion and epithelial–mesenchymal transition. Oncol Res. 2017;25(9):1607. doi:10.3727/096504017X14938093512742
   PubMedGoogle Scholar
• Zhu J, Li B, Xu M, et al. Graphene oxide promotes cancer metastasis through associating with plasma membrane to promote TGF-β signaling-dependent epithelial–mesenchymal transition. ACS Nano. 2020;14(1):818–827. doi:10.1021/acsnano.9b07891
   PubMedGoogle Scholar
• Shirley AJ, Schweeberg S, Waag T, et al. The influence of differently functionalized nanodiamonds on proliferation, apoptosis and EMT/MET phenomena in 2D and 3D tumor cell cultures. J Mater Chem B. 2021;9(45):9395–9405. doi:10.1039/D1TB01739J
   PubMedGoogle Scholar
• Lin C, Ren Z, Yang XI, et al. Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. Cancer Lett. 2020;472:81–96. doi:10.1016/j.canlet.2019.12.015
   PubMedGoogle Scholar
• Bi Q, Tang S, Xia L, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012;7(6):e40169. doi:10.1371/journal.pone.0040169
   PubMed Web of Science ®Google Scholar
• Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci. 2018;19(5):1308. doi:10.3390/ijms19051308
   PubMed Web of Science ®Google Scholar
• Cevenini A, Orrù S, Mancini A, Alfieri A, Buono P, Imperlini E. Molecular signatures of the insulin-like growth factor 1-mediated epithelial-mesenchymal transition in breast, lung and gastric cancers. Int J Mol Sci. 2018;19(8):2411. doi:10.3390/ijms19082411
   PubMed Web of Science ®Google Scholar
• El Tayebi HM, Waly AA, Assal RA, Hosny KA, Esmat G, Abdelaziz AI. Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett. 2015;10(5):3206–3212. doi:10.3892/ol.2015.3725
   PubMed Web of Science ®Google Scholar
• Burnett M, Abuetabh Y, Wronski A, et al. Graphene oxide nanoparticles induce apoptosis in wild-type and CRISPR/Cas9-IGF/IGFBP3 knocked-out osteosarcoma cells. J Cancer. 2020;11(17):5007. doi:10.7150/jca.46464
   PubMed Web of Science ®Google Scholar
• Leroy K, Silva Costa CJ, Pieters A, et al. Expression and functionality of connexin-based channels in human liver cancer cell lines. Int J Mol Sci. 2021;22(22):12187. doi:10.3390/ijms222212187
   PubMed Web of Science ®Google Scholar
• Jung CW, Song TJ, Lee KO, et al. Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules. Int J Mol Med. 2012;29(6):1158–1164. doi:10.3892/ijmm.2012.951
   PubMedGoogle Scholar
• Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12(18):5369–5376. doi:10.1158/1078-0432.CCR-05-2722
   PubMed Web of Science ®Google Scholar
• Zhang X, Fan Q, Li Y, et al. Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of Hippo signaling. Oncotarget. 2017;8(18):29785. doi:10.18632/oncotarget.14523
   PubMedGoogle Scholar
• Jang MK, Su Kim H, Chung YH. Clinical aspects of tumor necrosis factor-α signaling in hepatocellular carcinoma. Curr Pharm Design. 2014;20(17):2799–2808. doi:10.2174/13816128113199990587
   PubMed Web of Science ®Google Scholar
• Xu ZW, Yan SX, Wu HX, et al. The influence of TNF-α and Ang II on the proliferation, migration and invasion of HepG2 cells by regulating the expression of GRK2. Cancer Chemoth Pharm. 2017;79(4):747–758. doi:10.1007/s00280-017-3267-z
   PubMedGoogle Scholar
• Fuchs BC, Hoshida Y, Fujii T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59(4):1577–1590. doi:10.1002/hep.26898
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen D, Ning F, Du J, Wang H. EGF is highly expressed in hepatocellular carcinoma (HCC) and promotes motility of HCC cells via fibronectin. J Cell Biochem. 2018;119(5):4170–4183. doi:10.1002/jcb.26625
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin W, Chen X, Wei G, Zhu H, Xing S. Tanshinone IIA reverses EGF-and TGF-β1-mediated epithelial-mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathway. Oncol Lett. 2019;18(6):6554–6562. doi:10.3892/ol.2019.11032
   PubMed Web of Science ®Google Scholar
• Wang D, Yang E, Cheng LY. Effects of IFN-gamma, TNF-alpha and EGF on the expression of HLA class I antigen and the proliferation of human hepatocellular carcinoma HepG2 cells. Anticancer Res. 1997;17(1A):181–188.
   PubMedGoogle Scholar
• Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012;2012:1–11. doi:10.1155/2012/306879
   Google Scholar
• Yamauchi Y, Kohyama T, Takizawa H, et al. Tumor necrosis factor-α enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-β1. Exp Lung Res. 2010;36(1):12–24. doi:10.3109/01902140903042589
   PubMed Web of Science ®Google Scholar
• Zhang X. Activated monocyte-derived TNF-α upregulates HGF/c-Met to trigger EMT of hepatoma cells. In Proceedings of the 2020 12th International Conference on Bioinformatics and Biomedical Technology; 2020:127–133.
   Google Scholar
• Liao Y, Wang W, Huang X, Sun Y, Tian S, Cai P. Reduced graphene oxide triggered epithelial-mesenchymal transition in A549 cells. Sci Rep. 2018;8:15188. doi:10.1038/s41598-018-33414-x
   PubMedGoogle Scholar
• Hu CT, Wu JR, Chang TY, Cheng CC, Wu WS. The transcriptional factor Snail simultaneously triggers cell cycle arrest and migration of human hepatoma HepG2. J Biomed Sci. 2008;15(3):343–355. doi:10.1007/s11373-007-9230-y
   PubMedGoogle Scholar
• Scheau C, Badarau IA, Costache R, et al. The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol. 2019;2019:1–10. doi:10.1155/2019/9423907
   Google Scholar
• Du H, Gu J, Peng Q, et al. Berberine suppresses EMT in liver and gastric carcinoma cells through combination with TGFβR regulating TGF-β/Smad pathway. Oxid Med Cell Longev. 2021;2021:1–21. doi:10.1155/2021/2337818
   Google Scholar
• Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83. doi:10.1038/35000025
   PubMed Web of Science ®Google Scholar
• Helal TES, Aref A, Gomaa AI, et al. Epithelial-mesenchymal transition markers in HCV-associated hepatocellular carcinoma: a multivariate follow up study. Asian Pac J Cancer Prev. 2022;23(3):839. doi:10.31557/APJCP.2022.23.3.839
   PubMedGoogle Scholar